Weekly channel feed – Endpoints News

Weekly channel feed

Biogen pressed against the wall as more stakeholders side against Aduhelm; Prime time for CRISPR 3.0?; and more

4 years ago

Storm brews around Aduhelm as FDA requests probe; Dissecting pipeline disasters; Bob Nelsen is going Really Big; and more

4 years ago

Watch out, Pfizer and Moderna; Anti-aging breakthrough in mice?; Neuro for the new GSK; and more

4 years ago

Are 'platform plays' here to stay?; The Aduhelm saga continues to unfold; A new GSK?; and more

4 years ago

Aduhelm OK 'bittersweet' for ALS advocates; Contrasting Covid-19 vaccine readouts; GSK joins TIGIT battle; and more

4 years ago

Unpacking the Aduhelm decision, Vertex's half full glass, a $525M J&J breakup, and more

4 years ago

What aducanumab means for Alzheimer's, unpacking a safety barrier in CAR-T, the push to upgrade a key ALS trial tool, and more

4 years ago

Latest news: Amgen's landmark OK for KRAS drug, inside Vertex 3.0, the big hunt for CAR-T in solid tumors, and more

4 years ago

Latest news on J&J’s NSCLC approval, Bristol Myers Squibb’s big TIGIT bet, #ASCO21 and more

5 years ago

$DNA is once again on NYSE; FDA clears Soliris challenger for the market; Flagship’s thinking big again with eRNA; and more

5 years ago

Roger Perlmutter’s new gig, Covid-19 IP drama, Vivek Ramaswamy's coach on the SPAC train, and more

5 years ago

Quiet end for flashy upstart, the PD-(L)1 reckoning that wasn't, Big Pharma's Covid-19 year, and more

5 years ago

Latest news: Committee votes to restart J&J vaccinations, checkpoint giants prep defense, underdog vaccine enters the spotlight, and more

5 years ago

Covid-19 vaccine halt drags on, an FDA appointment at long last, the great CRO consolidation, and more

5 years ago

The Endpoints 20 under 40, biotech's new normal, Stéphane Bancel's one regret, and more

5 years ago

Legendary biotech leader passes away, renewed tension around aducanumab, Merck's rare defeat, and more

5 years ago

AstraZeneca's Covid-19 vaccine woes, Moncef Slaoui resigns over sexual harassment claims, FDA acts tough, and more

5 years ago

Merck's C-suite shakeup, Eli Lilly stirs fresh Alzheimer's controvery, play by play of Amgen's $2B buyout, and more

5 years ago

Novartis' wild card blockbuster contender falls flat; Regulatory reckoning for checkpoint drugs looms; and more

5 years ago

The top 100 biopharma VCs, Bob Bradway places $2B bet in cancer, gene editing pioneer's new big idea, and more

5 years ago

The future of mRNA, J&J's vaccine adcomm, Merck's $1.85B autoimmune bet and more

5 years ago

A gene therapy leader stumbles, Medicxi's splashy 10-in-1 startup play, a radical HIV cure gets its shot, and biopharma's new top 50

5 years ago

First page Previous page 6 7 89